3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries
The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a handful of biopharma stocks, according to a Morgan Stanley analyst.
33 Stocks Moving In Monday’s Mid-Day Session
Gainers
Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dystrophic EB).
GSK, Vir’s Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19
GlaxoSmithKline plc (NYSE:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered via…
Benzinga Pro’s Top 5 Stocks To Watch For Tuesday, Nov. 9, 2021: AMD, HTZ, BBBY, RIVN, VIR
Today's 5 Stock Ideas:
Advanced Micro Devices (AMD) - Shares rallied more than 10% on Monday amid a report Meta (the company soon to be formerly known as Facebook (FB)) will use AMD chips for its data centers.
Vir Biotechnology Q3 EPS $0.85 Up From $(0.67) YoY, Sales $103.60M Up From $1.93M YoY
Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.85 per share. This is a 226.87 percent increase over losses of $(0.67) per share from the same period last year. The company reported $103.60 million in
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
GlaxoSmithKline Drops Research On Otilimab In COVID-19
GlaxoSmithKline Plc (NYSE:GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in…